Browse > Article
http://dx.doi.org/10.5322/JESI.2020.29.8.837

Effect of Momordica charantia on Glucagon Secretion in High-fat diet(HFD)/Streptozotocin(STZ)-induced Diabetic Rat  

Kim, Seong-Eun (Food Science R&D Center, Kolmar BNH Co. Ltd.)
Kim, Sang-Back (Skin & Natural products Lab. Kolmar Korea Co. Ltd.)
Kim, Seul Ki (Food Science R&D Center, Kolmar BNH Co. Ltd.)
Kim, Hyun-Kyu (Food Science R&D Center, Kolmar BNH Co. Ltd.)
Park, Byoungjun (Skin & Natural products Lab. Kolmar Korea Co. Ltd.)
Lee, Hak Sung (Food Science R&D Center, Kolmar BNH Co. Ltd.)
Publication Information
Journal of Environmental Science International / v.29, no.8, 2020 , pp. 837-846 More about this Journal
Abstract
In present study, we investigated the antidiabetic effect of Momordica charantia(as well known "bitter melon"). This study was conducted to determine antidiabetic mechanism of Bitter Melon Extract (BME). We measured blood glucose, insulin, glucagon level in a Sprague-Dawley rat model of high-fat diet/streptozotocin(HFD/STZ)-induced diabetes. Five experimental groups were used: normal, HFD/STZ, BME 62.5 mg/kg HFD/STZ, BME 125 mg/kg HFD/STZ and BME 250 mg/kg HFD/STZ. BME was orally administered to the rats every other day for 9 weeks. Results showed that fasting blood glucose levels were significantly lower in the BME 125 mg/kg(150.17 ± 20.22 mg/dL) and 250 mg/kg(124.17 ± 22.17 mg/dL) groups than in the vehicle group(188.83 ± 26.63 mg/dL)(p<0.05). In addition, glucagon levels were lower in the three BME treatment groups than in the vehicle group(p<0.05). Oral glucose tolerance tests revealed that the BME 250 mg/kg group had significantly(p<0.05) reduced 120-minute blood glucose levels and areas under the curve. Our results suggest that BME induces antidiabetic effects via the reduction of glucagon and blood glucose levels.
Keywords
Momordica charantia; Diabetes; Blood sugar; Glucagon; Health supplement;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Adeghate, E., Schattner, P., Dunn, E., 2006, An Update on the etiology and epidemiology of diabetes mellitus., Ann. N. Y. Acad. Sci., 1084, 1-29.   DOI
2 Ahmed, I., Adeghate, E., Sharma, A. K., Pallot, D. J., Singh, J., 1998, Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat., Diabetes. Res. Clin. Pract., 40, 145-151.   DOI
3 Beloin, N., Gbeassor, M., Akpagana, K., Hudson, J., de Soussa, K., Koumaglo, K., Arnason, J. T.. 2005, Ethnomedicinal uses of Momordica charantia (Cucurbitaceae) in Togo and relation to its phytochemistry and biological activity., J. Ethnopharmacol., 96, 49-55.   DOI
4 Bhat, G. A., Khan, H. A., Alhomida, A. S., Sharma, P., Singh, R., Paray, B. A., 2018, GLP-1 secretion in healthy and diabetic Wistar rats in response to aqueous extract of Momordica charantia., BMC Complement. Altern. Med., 18, 162.   DOI
5 Consoli, A., 1992, Role of Liver in Pathophysiology of NIDDM., Diabetes. Care., 15, 430-441.   DOI
6 Grover, J. K., Rathi, S. S., Vats V., 2002, Amelioration of experimental diabetic neuropathy and gastropathy in rats following oral administration of plant(Eugenia jambolana, Mucuna pruriens and Tinospora cordifolia) extracts. Indian. J. Exp. Biol., 40, 273-276.
7 Grover, J. K., Vats, V., Rathi, S. S., Dawar, R., 2001, Traditional Indian anti-diabetic plants attenuate progression of renal damage in streptozotocin induced diabetic mice. J. Ethnopharmacol., 76, 233-238.   DOI
8 Grover, J. K., Yadav, S. P., 2004, Pharmacological actions and potential uses of Momordica charantia: a review., J. Ethnopharmacol., 93, 123-132.   DOI
9 Jiang, G., Zhang, B. B., 2003, Glucagon and regulation of glucose metabolism., Am. J. Physiol. Endocrinol. Metab., 284, E671-E678.   DOI
10 Kim, J. W., Lee, Y. S., Seol, D. J., Cho, I. J., Ku, S. K., Choi, J. S., Lee, H. J.. 2018, Anti-obesity and fatty liver -preventing activities of Lonicera caerulea in high-fat diet-fed mice. Int. J. Mol. Med., 42, 3047-64.
11 Kim, Y. J., Kim, H. K., Lee, H. S., 2018, Hypoglycemic effect of standardized Chrysanthemum zawadskii ethanol extract in high-fat diet/streptozotocin-induced diabetic mice and rats., Food. Sci. Biotechnol., 27, 1771-1779.   DOI
12 Kyoung, S. P., 2018, DIABETES FACT SHEET IN KOREA. Korea Diabetes Association, Seoul, Korea.
13 Lee, M. Y., Kim, M. K., Park, J. S., Lee, S. B., You, J. H., Ahn, C. W., Kim, K. R., Kang, S. N., 2019, Higher Glucagon-to-Insulin Ration Is Associated With Elevated Glycated Hemoglobin Levels in Type 2 Diabetes Patients., Korean. J. Intern. Med., 34, 1068-1077.   DOI
14 Elekofehinti, O. O., Ariyo, E. O., Akinijiyan, M. O., Olayeriju, O. S., Lawal, A. O., Adanlawo, I. G., Rocha, J. B. T., 2018, Potential use of bitter melon(Momordica charantia) derived compounds as antidiabetics: In silico and in vivo studies. Pathophysiology., 25, 327-333.   DOI
15 Raman, A., Lau, C., 1996, Anti-diabetic properties phytochemistry of Momordica charantia L. (Cucurbitaceae)., Phytomedicine., 2, 349-362.   DOI
16 Stratton, I. M., Adler, A. I., Neil, H. A. W., Matthews, D. R., Manley, S. E., Cull, C. A., Hadden, D., Turner, R. C., Holman, R. R., 2000, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ., 321, 405-412.   DOI
17 Rathi, S. S., Grover, J. K., Vikrant, V., Biswas, N. R.. 2002, Prevention of experimental diabetic cataract by Indian Ayurvedic plants extracts., Phytother. Res., 16, 774-777.   DOI
18 Shih, C. C., Shlau, M. T., Lin, C. H., Wu, J. B., 2014, Momordica charantia Ameliorates Insulin Resistance and Dyslipidemia with Altered Hepatic Glucose Prodcution and Fatty Acid Synthesis and AMPK Phosphorylation in High-fat-fed Mice., Phytother. Res., 28, 363-371.   DOI
19 Son, H. S., 2008, Early Diagnosis of Diabetes Mellitus. J. Korean. Med. Assoc., 51, 813-817.   DOI
20 Vikrant, V., Grover, J. K., Tandon, N., Rathi, S. S., Gupta, N., 2001, Treatment with extracts of Momordica charantia and Eugenia jambolana prevents hyperglycemia and hyperinsulinemia in fructose fed rats. J. Ethnopharmacol., 76, 139-143.   DOI
21 Wang, L., Waltenberger, B., Pferschy-Wenzig, E. M., Blunder, M., Liu, X., Malanier, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., Schuster, D., Kopp, B., Bauer, R., Stuppner, H., Dirsch, V. M., Atanasov, A. G., 2014, Natural product agonists of peroxisome proliferator-activated receptor gamma ($PPAR{\gamma}$): a review. Biochem. Pharmacol., 92, 73-89.   DOI